Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis

被引:12
|
作者
Allen, John M. [1 ,2 ]
Bakare, Lolade [3 ]
Casapao, Anthony M. [4 ]
Klinker, Ken [5 ]
Childs-Kean, Lindsey M. [5 ]
Pomputius, Ariel F. [6 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Orlando, FL 32827 USA
[2] Univ Cent Florida, Coll Med, Dept Internal Med, Orlando, FL 32816 USA
[3] Univ Florida, Coll Pharm, Orlando, FL USA
[4] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Jacksonville, FL USA
[5] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
[6] Univ Florida, Hlth Sci Ctr Lib, Biomed & Hlth Informat Serv, Gainesville, FL USA
关键词
Bacteremia; Cefazolin; Infection; Meta-analysis; Penicillins; Staphylococcus aureus; BETA-LACTAMS; NAFCILLIN; BACTEREMIA; OXACILLIN; MORTALITY; OUTCOMES; THERAPY; SAFETY;
D O I
10.1007/s40121-019-00259-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Methicillin-susceptible Staphylococcus aureus (MSSA) is a common cause of infection in humans. Beta-lactam antibiotics are the preferred agents, with anti-staphylococcal penicillins (ASPs) or the first-generation cephalosporin, cefazolin, favored by clinicians. Recent studies comparing the two strategies suggest similar outcomes between the agents. The purpose of this meta-analysis was to explore differences between cefazolin and ASPs for the treatment of MSSA infections. Methods We performed a meta-analysis with trial sequential analysis (TSA) of observational or cohort studies using a random-effects model. Two blinded reviewers independently assessed studies for inclusion, risk of bias, and data extraction. The primary outcome was all-cause mortality. Secondary outcomes included clinical failure, infection recurrence, and antibiotic discontinuation due to adverse events. Subgroup analyses were conducted for the primary outcome by type of ASP, studies with a high percentage of deep-seated infections, and studies of low to moderate risk of bias. Results After performing a comprehensive search of the literature, and screening for study inclusion, 19 studies (13,390 patients) were included in the final meta-analysis. Fifteen of the 19 studies (79%) were judged as having a low or moderate risk of bias. Use of cefazolin was associated with lower all-cause mortality [odds ratio (OR) 0.71, 95% confidence interval (CI) 0.56-0.91, p = 0.006, I-2 = 28%], clinical failure (OR 0.55, 95% CI 0.41-0.74, p < 0.001, I-2 = 0%), and antibiotic discontinuation due to adverse events (OR 0.25, 95% CI 0.16-0.39, p < 0.001, I-2 = 23%). Infection recurrence was higher in the cefazolin patients (OR 1.41, 95% CI 1.04-1.93, p = 0.03, I-2 = 0%). Conclusion This meta-analysis demonstrated that the use of cefazolin was associated with significant reductions in all-cause mortality, clinical failure, and discontinuation due to adverse events, but was associated with an increased risk of infection recurrence. Funding University of Florida Open Access Publishing Fund funded the Rapid Service Fees.
引用
收藏
页码:671 / 686
页数:16
相关论文
共 50 条
  • [1] Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis
    John M. Allen
    Lolade Bakare
    Anthony M. Casapao
    Ken Klinker
    Lindsey M. Childs-Kean
    Ariel F. Pomputius
    Infectious Diseases and Therapy, 2019, 8 : 671 - 686
  • [2] Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review
    Loubet, P.
    Burdet, C.
    Vindrios, W.
    Grall, N.
    Wolff, M.
    Yazdanpanah, Y.
    Andremont, A.
    Duval, X.
    Lescure, F-X
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (02) : 125 - 132
  • [3] Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis
    Lee, Benjamin J.
    Wang, Sheila K.
    Constantino-Corpuz, Janie K.
    Apolinario, Kristel
    Nadler, Barbara
    McDanel, Jennifer S.
    Scheetz, Marc H.
    Rhodes, Nathaniel J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (03) : 225 - 233
  • [4] Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia
    Weis, S.
    Kesselmeier, M.
    Davis, J. S.
    Morris, A. M.
    Lee, S.
    Scherag, A.
    Hagel, S.
    Pletz, M. W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (07) : 818 - 827
  • [5] Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis
    Changcheng Shi
    Yubo Xiao
    Qi Zhang
    Qingyu Li
    Fei Wang
    Jing Wu
    Nengming Lin
    BMC Infectious Diseases, 18
  • [6] Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis
    Shi, Changcheng
    Xiao, Yubo
    Zhang, Qi
    Li, Qingyu
    Wang, Fei
    Wu, Jing
    Lin, Nengming
    BMC INFECTIOUS DISEASES, 2018, 18
  • [7] Re-Appraisal of the Effectiveness and Adverse Reaction between Cefazolin and Anti-Staphylococcal Penicillins for Treating Patients with Methicillin-Sensitive Staphylococcus aureus Bacteremia: Comprehensive Meta-analysis and Trial Sequential Analysis
    Chen, Chang-Hua
    Chen, Yu-Min
    Chen, Hsien-Meng
    Chang, Yu-Jun
    Lin, Li-Jhen
    Yen, Hua-Cheng
    INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2021, 55 (01) : 288 - 303
  • [8] 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study'-author's reply
    Lecomte, Raphael
    Deschanvres, Colin
    Coudol, Sandrine
    Wargny, Matthieu
    Camou, Fabrice
    Boutoille, David
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (08) : 1180 - 1181
  • [9] Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia
    Monogue, Marguerite L.
    Ortwine, Jessica K.
    Wei, Wenjing
    Eljaaly, Khalid
    Bhavan, Kavita P.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2018, 11 (05) : 727 - 731
  • [10] Ceftriaxone versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia
    Mohamed, Adham
    Bennett, Nicholas
    Ploetz, Jeannette
    Aragon, Laura
    Kennedy, Kevin
    Boyd, Sarah
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)